If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
57
results.
Updated on
20/08/2026 [06:45:00]
Absstract of: WO2025080543A1
Provided herein are methods of predicting the responsiveness of a lymphoma patient to a cancer treatment. Also provided herein are methods of treating a lymphoma patient based on predicting the responsiveness of the lymphoma patient to a cancer treatment.
Absstract of: WO2025080911A1
The present disclosure is directed to methods of treating multiple myeloma. The present disclosure is directed to methods of treating newly diagnosed multiple myeloma in a subject in need thereof, for example, by subcutaneously administering to the subject a pharmaceutical composition comprising an anti-CD38 antibody in combination with bortezomib, lenalidomide, and dexamethasone.
Absstract of: US20260232638A1
0000 There is provided a compound of formula I or a pharmacologically acceptable salt thereof:
0000
for use in the treatment of a brain cancer selected from a MGMT positive astrocytic brain tumor, a metastatic brain cancer and primary CNS lymphoma and a method of treating said brain cancers in a patient in need thereof comprising administering to the patient said compound of formula I or a pharmacologically acceptable salt thereof.
Absstract of: US20260234264A1
The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
Absstract of: US20260234146A1
The present application relates to use of a hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHI) in rare anemia. Specifically disclosed in the present application is use of certain hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) in the treatment of anemia of myelodysplastic syndromes (MDS anemia), beta-thalassemia (β-thalassemia), and/or sickle cell disease (sickle cell anemia, SCD anemia).
Absstract of: US20260232681A1
0000 Described herein is N-4-4-(4-morpholinyl)-7H-pyrrolo2,3-dpyrimidin-6-ylphenyl-4-3(R)-(1-oxo-2-propen-1-yl)amino-1-piperidinylmethyl-2-pyridinecarboxamide (Compound A) (Formula I), including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.
0000
Absstract of: US20260232824A1
0000 The present disclosure provides anti-CD180 binding molecules and uses thereof. In one embodiment, the anti-CD180 binding molecules are anti-CD180 antibodies. Also provided are anti-CD180 antibody-drug conjugates (ADCs) comprising a CD180-high expressing tumor-targeting monoclonal antibody or antigen-binding fragment thereof, a cytotoxic drug payload and a linker moiety conjugating the CD180-high expressing tumor-targeting antibody or the antigen-binding fragment thereof to the cytotoxic drug payload. The anti-CD180 antibodies or the antigen binding fragments thereof, and the ADCs comprising the anti-CD180 antibodies, or the antigen binding fragments thereof are useful in treating diseases, such as acute myeloid leukemia, mantle cell lymphoma, multiple myeloma. follicular lymphoma, B-acute lymphoblastic leukemia, or diffuse large B-cell lymphoma.
Absstract of: US20260234248A1
0000 This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low peripheral cancerous cell burden. This invention also provides a method for treating a subject afflicted with a hematologic malignancy and having a high peripheral cancerous cell burden, comprising (i) medically lowering the subject's peripheral cancerous cell burden, and (ii) while the subject's peripheral cancerous cell burden is still low, administering to the subject an agent targeting a hematologic malignancy-associated antigen. Particularly envisioned are the subject methods for treating acute myeloid leukemia using an anti-CD33 antibody labeled with an alpha-emitting isotope, such as <225>Ac-HuM195.
Absstract of: US20260234129A1
The present invention relates to a novel imidazole derivative and a pharmaceutical composition for treating protein kinase-associated diseases, comprising same as an active ingredient. More specifically, the present invention relates to a novel imidazole derivative and a pharmaceutical composition comprising same as an active ingredient, the derivative inhibiting protein kinase activity so as to prevent or treat cancer diseases. In addition, the compound and the pharmaceutical composition, comprising same as an active ingredient, of the present invention, effectively inhibit FLT3 kinase activity, and thus can be effectively used for preventing or treating mutant FLT3-associated diseases, particularly acute myeloid leukemia.
Absstract of: AU2024415673A1
Provided is a circular RNA encoding CARs and the use thereof to create immune cells that target specific diseases, e. g., lymphoma, multiple myeloma and leukemia and auntoimmune diseases, such as systemic lupus erythematousus, lupus nephritis and myasthenia gravis.
Absstract of: US20260232683A1
0000 Provided herein are methods of treating and/or managing non-Hodgkin lymphoma, which comprise administering to a patient 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (“Compound A, A-S, or A-R”), or an enantiomer or mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with glofitamab or mosunetuzumab.
Absstract of: US20260232807A1
A method of impairing cancer cell growth in a mammal having leukemia or lymphoma is disclosed, the method including administering to the mammal a pharmaceutical composition comprising a pharmacologically active amount of (+)-BAY K8644 as a monotherapy or in combination with the tyrosine kinase inhibitor, Ibrutinib.
Absstract of: US20260234207A1
0000 The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-8, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or a host cell having the nucleic acid molecule integrated into the genome, as well as a method for preparing keratin YK93-8 and a pharmaceutical composition of keratin YK93-8. Further provided is the use of the above-mentioned keratin YK93-8 and other products in the preparation of drugs, such as a drug for treating hyperplasia of prostate, lymphoma, melanoma, breast cancer, lung cancer and uterine myoma, an analgesic, a lactation drug and a coagulant.
Absstract of: US20260234630A1
0000 Provided herein are methods of treating multiple myeloma, including multiple myeloma that is resistant to at least one therapeutic agent, comprising administering to a subject with multiple myeloma an inhibitor of Ubiquitin-Like with PHD and Ring Finger Domains 1 (UHRF1).
Absstract of: WO2026170226A1
This disclosure provides methods for imaging of samples for diagnosis of lymphoid neoplasms, lymphocytic autoimmune disease, and other conditions related to clonal expansion of lymphocytes. Using these methods, individual lymphocytes can be imaged in situ to determine tissue-wide clonality based on rearrangement of T cell receptor gene segments. Post hoc bulk sequencing allows for complementarity determining sequences to be mapped back to individual lymphocyte clones in super resolution images. In additional to its clinical applications in histopathology, these methods are also useful for the study of cellular and immunologic processes related to lymphoproliferative and autoimmune disorders.
Absstract of: US20260232732A1
The present invention provides therapeutics for the treatment of CCR9-positive cancers such as T-cell acute lymphoblastic leukemia. In particular, the present invention provides a CCR9 targeting moiety. The present invention furthermore relates to a CCR9 targeting moiety comprising a further targeting moiety, preferably a CD1a targeting moiety, a dual CAR comprising a CCR9 and a CD1a targeting moiety, their use in the treatment of CCR9 and/or CD1a positive cancers, and the use of a CCR9 targeting moiety and a separate CD1a targeting moiety for such treatment.
Absstract of: US20260234243A1
0000 Polyspecific anti-glycosaminoglycan (GAG) antibodies and methods of use thereof for directly killing cancer cells. The anti-GAG antibodies can be used for purging cancer cells from autologous stem cell transplants (ASCT) or autologous bone marrow transplants (ABMT). The cancer cells may be multiple myeloma, Hodgkin's lymphoma, neuroblastoma, or any other cancer that expresses a membrane-tethered heparan sulfate proteoglycan (HSPG), such as syndecan or glypican.
Absstract of: EP4789716A2
0001 Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have myelodysplastic syndrome. Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having myelodysplastic syndrome.
Absstract of: US20260226119A1
0000 Disclosed are compositions and methods for engineered peptide inhibitors of NLRP3 inflammasome and methods of their use in the treatment of Myelodysplastic Syndromes.
Absstract of: US20260224578A1
0000 The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.
Absstract of: US20260226431A1
The disclosure provides Moloney murine leukemia virus (MMLV) reverse transcriptase (RTase) mutants. The disclosure as provides suitable amino acid positions in MMLV RTase for mutagenesis and methods and kits for using MMLV RTase mutants to synthesize cDNA from RNA templates.
Absstract of: US20260224733A1
0000 Nanoparticles comprising an outer surface covalently conjugated to 1,4-Bis(1,4,8,11-tetraazacyclotetradecan-1-yl)methylbenzene (AMD3100) or a derivative thereof capable of binding to C-X-C chemokine receptor type 4 (CXCR4) are provided. Methods for of treating a CXCR4 positive cancer, such as multiple myeloma or acute myeloid leukemia, in a subject in need thereof, methods of determining suitability for treatment and methods of covalently linking a molecule comprising a secondary amine to a lipid nanoparticle, are also provided.
Absstract of: US20260226048A1
0000 Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I), (II), or (III)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
Absstract of: US20260224567A1
0000 Provided herein are methods for treating neuroblastoma characterized as having genetic aberrations in ALK, FAK, and/or MYCN with ESK440.
Nº publicación: US20260226175A1 06/08/2026
Applicant:
PURETECH LYT INC [US]
PureTech LYT, Inc.
Absstract of: US20260226175A1
Disclosed herein are combined therapies for treating a hematologic malignancy (e.g., acute myeloid leukemia (AML), or myelodysplastic syndromes (MDS)), using an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17), and one or more chemotherapeutics, e.g., a Bcl2 inhibitor such as venetoclax, a hypomethylating agent (HMA), or a combination thereof.
BOPI
Electronic site
